ValuEngine cut shares of PURE Bioscience (OTCMKTS:PURE) from a hold rating to a sell rating in a research note issued to investors on Friday, November 10th.
PURE Bioscience (OTCMKTS:PURE) opened at $1.00 on Friday. PURE Bioscience has a twelve month low of $0.75 and a twelve month high of $1.36.
ILLEGAL ACTIVITY NOTICE: “PURE Bioscience (PURE) Rating Lowered to Sell at ValuEngine” was first reported by The Ledger Gazette and is the property of of The Ledger Gazette. If you are viewing this piece of content on another domain, it was illegally copied and republished in violation of United States and international copyright and trademark legislation. The correct version of this piece of content can be accessed at https://ledgergazette.com/2017/11/22/pure-bioscience-pure-downgraded-by-valuengine.html.
About PURE Bioscience
PURE Bioscience, Inc is focused on developing and commercializing antimicrobial products that provide solutions to the health and environmental challenges of pathogen and hygienic control. The Company’s technology platform is based on stabilized ionic silver and its products contain silver dihydrogen citrate (SDC).
To view ValuEngine’s full report, visit ValuEngine’s official website.
Receive News & Ratings for PURE Bioscience Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for PURE Bioscience and related companies with MarketBeat.com's FREE daily email newsletter.